恶性肿瘤骨转移免疫治疗研究进展  

Advances in Immunotherapy of Bone Metastases in Malignant Tumors

作　　者：李佳莉 刘鹏杰[1] LI Jiali;LIU Pengjie(Department of Nuclear Medicine,Yunnan Provincial Hospital of Oncology,Kunming 650118,China)

机构地区：[1]云南省肿瘤医院核医学科,昆明650118

出　　处：《医学综述》2024年第21期2631-2637,共7页Medical Recapitulate

摘　　要：骨转移是恶性肿瘤最常见的并发症之一,严重影响患者的生活质量和预后。近年,恶性肿瘤骨转移治疗在提高患者生活质量、延长患者生存时间方面已取得一定进展,但也存在一定局限性。免疫治疗作为一种新兴的抗癌治疗手段,已引起广泛关注,其可部分提高骨转移患者的生存获益。因此,积极探索肿瘤免疫治疗靶点具有重要的临床意义。未来深入研究免疫治疗在恶性肿瘤骨转移中的作用机制,可以为疾病的治疗提供新思路。Bone metastasis is one of the most common complications of malignant tumors,which seriously affects the quality of life and prognosis of the patients.In recent years,the treatment of bone metastasis of malignant tumors has made some progress in improving the quality of life and prolonging the survival time of the patients,but there are also some limitations.As a new anticancer treatment,immunotherapy has attracted wide attention,which can partially improve the survival benefit of the patients with bone metastases.Therefore,actively exploring tumor immunotherapy targets has great clinical significance.Further research on the mechanism of immunotherapy in bone metastasis of malignant tumors in the future may provide new ideas for the treatment.

关 键 词：恶性肿瘤 骨转移 免疫治疗 免疫调节 

分 类 号：R738.1[医药卫生—肿瘤]